HRP20192142T1 - Stabilni oftalmološki pripravak, posebno za liječenje sindroma suhog oka - Google Patents

Stabilni oftalmološki pripravak, posebno za liječenje sindroma suhog oka Download PDF

Info

Publication number
HRP20192142T1
HRP20192142T1 HRP20192142TT HRP20192142T HRP20192142T1 HR P20192142 T1 HRP20192142 T1 HR P20192142T1 HR P20192142T T HRP20192142T T HR P20192142TT HR P20192142 T HRP20192142 T HR P20192142T HR P20192142 T1 HRP20192142 T1 HR P20192142T1
Authority
HR
Croatia
Prior art keywords
preparation
preparation according
oligosaccharide
salts
dry eye
Prior art date
Application number
HRP20192142TT
Other languages
English (en)
Inventor
Fabrice Mercier
Léopold SCHMETTERER
Original Assignee
Laboratoires Théa
Medical University Of Vienna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Théa, Medical University Of Vienna filed Critical Laboratoires Théa
Publication of HRP20192142T1 publication Critical patent/HRP20192142T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (9)

1. Oftalmološki pripravak naznačen time da sadrži hijaluronsku kiselinu, ili jednu od njenih soli, molekulske težine između 100 do 800 kDa i oligosaharid.
2. Pripravak prema patentnom zahtjevu 1, naznačen time da je oligosaharid diholozid.
3. Pripravak prema patentnom zahtjevu 1 ili 2, naznačen time da hijaluronska kiselina ili jedna od njenih soli čini između 0.05 i 0.5 g u 100 ml pripravka, poželjno između 0.1 i 0.2 g/100 ml, više poželjno 0.15 g/100 ml.
4. Pripravak prema jednom od prethodnih patentnih zahtjeva, naznačen time da oligosaharid čini između 0.5 i 5 g u 100 ml pripravka, poželjno između 2 i 4 g/100 ml, više poželjno 3 g/100 ml.
5. Pripravak prema jednom od prethodnih patentnih zahtjeva, naznačen time da pripravak pokazuje pri 25°C viskoznost po Brookfield-u nižu od 50 mPa.s, poželjno koja je između 2 i 15 mPa.s.
6. Pripravak prema jednom od prethodnih patentnih zahtjeva, naznačen time da je lišen bilo kojeg konzervirajućeg agensa antimikrobnog tipa.
7. Pripravak prema patentnim zahtjevima od 1 do 6 naznačen time da pripravak ne sadrži nijedan drugi oftalmološki aktivni agens.
8. Pripravak prema patentnim zahtjevima od 1 do 6, naznačen time da pripravak dalje obuhvaća neki aktivni agens odabran iz sljedeće skupine: aceklidin, acetazolamid, aciklovir, anekortav, apraklonidin, atropin, azapentacen, azelastin, bacitracin, befunolol, betametazon, betaksolol, bimatoprost, brimonidin, brinzolamid, karbahol, karteolol, celecoksib, kloramfenikol, klortetraciklin, ciprofloksacin, kromoglicat, ciclopentolat, ciklosporin, dapiprazol, demekarium, deksametazon, diklofenak, diklorfenamid, dipivefrin, dorzolamid, ehotiofal, emedastin, epinastin, epinefrin, eritromicin, etoksizolamid, eukatropin, fludrokortison, fluorometolon, flurbiprofen, fomivirsen, framicetin, ganciklovir, gatifloksacin, gentamicin, homatropin, hidrokortizon, idoksuridin, indometacin, izoflurofat, ketorolak, ketotifen, latanoprost, levobetaksolol, levobunolol, levokabastin, levofloksacin, lodoksamid, loteprednol, medrison, metazolamid, metipranolol, moksifloksacin, nafazolin, natamicin, nedokromil, neomicin, norfloksacin, ofloksacin, olopatadin, oksimetazolin, pemirolast, pegaptanib, fenilefrin, fizostigmin, pilokarpin, pindolol, pirenoksin, polimiksin B, prednizolon, proparakain, ranibizumab, rimeksolon, skopolamin, sezolamid, skvalamin, sulfacetamid, suprofen, tetrakain, tetraciklin, tetrahidrozolin, tetrizolin, timolol, tobramicin, travoprost, triamcinulon, trifluorometazolarnid, trifluridin, trimetoprim, tropikamid, unoproston, vidarbin, ksilometazolin, farmaceutski potvrđene soli, ili bilo koja njihova kombinacija.
9. Pripravak prema jednom od prethodnih patentnih zahtjeva naznačen time da je za upotrebu u liječenju očnih bolesti, kao što je suho oko.
HRP20192142TT 2014-02-28 2019-11-28 Stabilni oftalmološki pripravak, posebno za liječenje sindroma suhog oka HRP20192142T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1451662A FR3018045B1 (fr) 2014-02-28 2014-02-28 Composition ophtalmique remanente, notamment pour le traitement de la secheresse oculaire
PCT/FR2015/050499 WO2015136186A1 (fr) 2014-02-28 2015-03-02 Composition ophtalmique rémanente, notamment pour le traitement de la sécheresse oculaire
EP15713215.0A EP3110425B1 (fr) 2014-02-28 2015-03-02 Composition ophtalmique rémanente, notamment pour le traitement de la sécheresse oculaire

Publications (1)

Publication Number Publication Date
HRP20192142T1 true HRP20192142T1 (hr) 2020-02-21

Family

ID=50624806

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192142TT HRP20192142T1 (hr) 2014-02-28 2019-11-28 Stabilni oftalmološki pripravak, posebno za liječenje sindroma suhog oka

Country Status (13)

Country Link
EP (1) EP3110425B1 (hr)
CY (1) CY1122457T1 (hr)
DK (1) DK3110425T3 (hr)
ES (1) ES2760523T3 (hr)
FR (1) FR3018045B1 (hr)
HR (1) HRP20192142T1 (hr)
HU (1) HUE047396T2 (hr)
LT (1) LT3110425T (hr)
PL (1) PL3110425T3 (hr)
PT (1) PT3110425T (hr)
RS (1) RS59721B1 (hr)
SI (1) SI3110425T1 (hr)
WO (1) WO2015136186A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000008299A1 (it) * 2020-04-17 2021-10-17 Glycores 2000 Srl Composizione liquida oftalmica comprendente acido ialuronico lineare a basso peso molecolare
EP4039248A1 (en) * 2021-02-04 2022-08-10 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
EP4218717A1 (en) 2022-02-01 2023-08-02 Laboratoires THEA Ophthalmic composition comprising resveratrol for treating dry eye syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
CN1302812C (zh) * 2004-11-30 2007-03-07 中国海洋大学 含海藻糖和玻璃酸的眼部用药传递系统及其制备方法
TWI393567B (zh) * 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
SG176525A1 (en) * 2006-12-22 2011-12-29 Sigma Tau Ind Farmaceuti Gel useful for the delivery of ophthalmic drugs
CN101691479B (zh) * 2009-09-25 2013-01-16 海昌隐形眼镜有限公司 一种角膜接触镜保存液组合物及其制备方法
CN101691478A (zh) * 2009-09-25 2010-04-07 海昌隐形眼镜有限公司 含海藻糖的角膜接触镜护理组合物及其制备方法
US20110319502A1 (en) * 2010-06-25 2011-12-29 Coffey Martin J Compositions and Methods for Enhancing Reduction of Spore-Forming Microorganisms
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition

Also Published As

Publication number Publication date
PL3110425T3 (pl) 2020-03-31
HUE047396T2 (hu) 2020-04-28
EP3110425A1 (fr) 2017-01-04
PT3110425T (pt) 2019-12-11
DK3110425T3 (da) 2019-12-09
FR3018045A1 (fr) 2015-09-04
WO2015136186A1 (fr) 2015-09-17
LT3110425T (lt) 2019-12-10
FR3018045B1 (fr) 2017-06-16
CY1122457T1 (el) 2021-01-27
EP3110425B1 (fr) 2019-11-13
ES2760523T3 (es) 2020-05-14
RS59721B1 (sr) 2020-01-31
SI3110425T1 (sl) 2020-01-31

Similar Documents

Publication Publication Date Title
HRP20231277T1 (hr) Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije
HRP20192142T1 (hr) Stabilni oftalmološki pripravak, posebno za liječenje sindroma suhog oka
JP2014513073A5 (hr)
JP2013502460A5 (hr)
WO2012063237A3 (en) Buffered ophthalmic compositions and methods of use thereof
AU2007339790B2 (en) Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
WO2013061205A3 (en) (4 - phenylimidazol - 2 - yl) ethylamine derivatives usful as sodium channel modulators
AR069729A1 (es) Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas
AU2012307812A8 (en) Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
MX2012004848A (es) Compuestos heterociclicos triciclicos.
CU23856A3 (es) Composiciones que comprenden anticuerpo monoclonal chir-12.12
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
WO2010042843A3 (en) Composition and method for treating dry eye syndrome
WO2012103186A3 (en) Androgen composition for treating an opthalmic condition
RU2015102531A (ru) Офтальмологический состав и способ для облегчения пресбиопии
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
AU2011282681B2 (en) Preservative free bimatoprost and timolol solutions
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
RU2017139870A (ru) Новые агонисты npr-b
PL2036538T3 (pl) Farmaceutycznie trwała mieszanina składająca się z tymololu, dorzolamidu i brymonidyny
PE20141031A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
GR1008483B (el) Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης